EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 49 WEEK SUMMACTA DATA

被引：0

作者：

Burmester, Gerd R. ^{[1
,2
,3
]}

Rubbert-Roth, Andrea ^{[4
]}

Cantagrel, Alain ^{[5
]}

Hall, Stephen ^{[6
]}

Leszczynski, Piotr ^{[7
]}

Feldman, Daniel ^{[8
]}

Rangaraj, Madura J. ^{[9
]}

Roane, Georgia ^{[10
]}

Ludivico, Charles ^{[11
]}

Mysler, Eduardo F. ^{[12
]}

Wells, Chris ^{[13
]}

Bennett, Melanie ^{[13
]}

Vranic, Ivana ^{[13
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, D-10099 Berlin, Germany

[4] Klinikum Univ Koln, Dept Internal Med, Cologne, Germany

[5] Ctr Hosp Univ Toulouse, Dept Rheumatol, Toulouse, France

[6] Cabrini Med Ctr, Dept Rheumatol, Malvern, Australia

[7] Poznan Univ Med Sci, Dept Physiotherapy Rheumatol & Rehabil, Poznan, Poland

[8] Univ Fed Sao Paulo, Dept Rheumatol, Sao Paulo, Brazil

[9] Arthrit & Diabet Clin Inc, Arthrit & Diabet Clin, Monroe, LA USA

[10] Rheumatol Associates, Dept Rheumatol, Charleston, SC USA

[11] East Penn Rheumatol Associates, Dept Rheumatol, Bethlehem, PA USA

[12] Org Med Invest, Dept Rheumatol, Buenos Aires, DF, Argentina

[13] Roche Prod Ltd, Dept Med, Garden City, Herts, England

来源：

RHEUMATOLOGY | 2014年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

O22

引用

页码：37 / 38

页数：2

共 50 条

[1] The Efficacy and Safety of Subcutaneous Tocilizumab Versus Intravenous Tocilizumab in Combination with Traditional DMARDs in Patients with RA at Week 97 (SUMMACTA)
Cividino, Alfred
Rubbert-Roth, Andrea
Cantagrel, Alain
Hall, Stephen
Leszczynski, Piotr
Feldman, Daniel
Rangaraj, Madura
Roane, Georgia
Ludivico, Charles
Mysler, Eduardo
Bennett, Melanie
Rowell, Lucy
Bao, Min
Burmester, Gerd
JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1285 - 1285
[2] The Efficacy and Safety Of Tocilizumab Subcutaneous Versus Tocilizumab Intravenous, In Combination With Traditional Dmards In Patients With RAAt 49 Weeks (SUMMACTA).
Burmester, Gerd R.
Rubbert-Roth, Andrea
Cantagrel, Alain G.
Hall, Stephen
Leszczynski, Piotr
Feldman, Daniel
Rangaraj, Madura J.
Roane, Georgia
Ludivico, Charles L.
Mysler, Eduardo F.
Wells, Chris
Bennett, Melanie
Vranic, Ivana
ARTHRITIS AND RHEUMATISM, 2013, 65 : S203 - S204
[3] Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
Burmester, Gerd R.
Rubbert-Roth, Andrea
Cantagrel, Alain
Hall, Stephen
Leszczynski, Piotr
Feldman, Daniel
Rangaraj, Madura J.
Roane, Georgia
Ludivico, Charles
Bao, Min
Rowell, Lucy
Davies, Claire
Mysler, Eduardo F.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) : 68 - 74
[4] THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB VERSUS INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RA AT WEEK 97 (SUMMACTA)
Burmester, G.
Rubbert-Roth, A.
Cantagrel, A.
Hall, S.
Leszczynski, P.
Feldman, D.
Rangaraj, M. J.
Roane, G.
Ludivico, C.
Mysler, E.
Bennett, M. J.
Rowell, L.
Bao, M.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 499 - 500
[5] THE EFFICACY AND SAFETY OF TOCILIZUMAB SUBCUTANEOUS VERSUS TOCILIZUMAB INTRAVENOUS, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RA AT 49 WEEKS (SUMMACTA) (ENCORE)
Burmester, G.
Rubbert-Roth, A.
Cantagrel, A.
Hall, S.
Leszczynski, P.
Feldman, D.
Rangaraj, M.
Roane, G.
Ludivico, C.
Mysler, E.
Nash, P.
Wells, C.
Bennett, M.
Vranic, I
INTERNAL MEDICINE JOURNAL, 2014, 44 : 25 - 26
[6] THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB VERSUS INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RA AT WEEK 97: RESULTS FROM THE SUMMACTA STUDY
Burmester, Gerd
Rubbert-Roth, Andrea
Cantagrel, Alain
Hall, Stephen
Leszczynski, Piotr
Feldman, Daniel
Rangaraj, Madura J.
Roane, Georgia
Ludivico, Charles
Mysler, Eduardo
Bennett, Melanie J.
Rowell, Lucy
Bao, Min
RHEUMATOLOGY, 2015, 54 : 71 - 72
[7] SUMMACTA: A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY OF THE SAFETY AND EFFICACY OF TOCILIZUMAB SUBCUTANEOUS (SC) VERSUS TOCILIZUMAB INTRAVENOUS (IV), IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA)
Hall, S.
Bird, P.
Rischmueller, M.
Rubbert-Roth, A.
Cantagrel, A.
Leszczynski, P.
Feldman, D.
Rangaraj, M.
Roane, G.
Ludivico, C.
Mysler, E.
Rowell, L.
Douglass, W.
Burmester, G.
INTERNAL MEDICINE JOURNAL, 2013, 43 : 13 - 13
[8] The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA).
Kivitz, Alan
Olech, Ewa
Borofsky, Michael A.
Zazueta, Beatriz M.
Navarro-Sarabia, Federico
Radominski, Sebastiao C.
Merrill, Joan T.
Wells, Chris
Wimalasundera, Sunethra
Douglass, Wendy
Pope, Janet E.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S604 - S605
[9] Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
McLaughlin, Maeve
Oestoer's, Andrew
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 429 - 437
[10] A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Burmester, Gerd R.
Rubbert-Roth, Andrea
Cantagrel, Alain
Hall, Stephen
Leszczynski, Piotr
Feldman, Daniel
Rangaraj, Madura J.
Roane, Georgia
Ludivico, Charles
Lu, Peng
Rowell, Lucy
Bao, Min
Mysler, Eduardo F.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 69 - 74

← 1 2 3 4 5 →